US & Canada
Analysis of federal and state cannabis reform shaping the North American market.
US & Canada · page 3
- Hemp Industry
House Agriculture Committee Advances Farm Bill With No Relief for Hemp Industry
The US House Agriculture Committee has voted to advance the 2026 farm bill without adopting any provisions to delay or repeal the incoming ban on intoxicating hemp.
- Industry Trends
US Cannabis Rescheduling: A Victory or a Federal Trap?
US cannabis rescheduling, much like President Donald Trump who is rightly credited for finally pushing it forward, has sucked all the oxygen out of the room for the last two years.
- Industry Trends
CRS Report Suggests 280E Could be Unconstitutional for Cannabis Businesses
According to recent analysis from the Congressional Research Service, cannabis businesses may not need to wait for rescheduling to challenge the now-notorious 280E tax burden, suggesting that it may be unconstitutional.
- Investment & Finance
Rescheduling Optimism Fades, Cannabis Stocks Follow
It is now nearly two months since President Donald Trump surprised the global cannabis industry by signing an executive order to drag the highly-anticipated cannabis rescheduling process out of the bureaucratic swamp.
- CBD Market
US Hemp Industry in Limbo as FDA Deadline for Cannabinoid Definitions Arrives
The Food and Drug Administration’s (FDA) 90-day deadline to clarify which cannabinoids will be banned under the incoming, controversial intoxicating hemp ban falls today.
- US & Canada
Republican Lawmakers Openly Defy Trump on Cannabis Rescheduling
As the excitement around President Donald Trump’s executive order to push forward with cannabis rescheduling has faded, the bill is now facing a much harsher reality.
- Clinical Research
Industry Leaders React to Historic Cannabis Rescheduling
President Donald Trump’s executive order directing federal agencies to move cannabis from Schedule I to Schedule III of the Controlled Substances Act represents the most significant shift in US drug policy in over half a century.
- Clinical Research
Cannabis Rescheduling is Here: Trump Signs Executive Order to Move Cannabis to Schedule III
After two years of speculation, rumours, stock swings, broken promises, and political theatre, President Donald Trump officially signed an executive order (EO) to push cannabis rescheduling through on Thursday (December 18).
- Industry Trends
Could Trump Actually Reschedule Cannabis This Time?
Cannabis Rescheduling fervour has once again reached dramatic levels following media reports that President Donald Trump is considering pushing through the long-touted move via an executive order.
- Hemp Industry
Federal Agencies ‘May Lack Resources’ to Enforce US Hemp Ban, Congressional Researchers Warn
The incoming changes to hemp classification in the US are already facing major issues, with the Government’s own Congressional Research Service (CRS) stating that it remains ‘unclear’ how it will be enforced in practice.
- CBD Market
Medicare CBD Coverage Proposed, But Federal Ban Threatens Entire Industry
Cannabis stocks enjoyed another spike last week following reports that the Centers for Medicare & Medicaid Services is preparing to authorise insurance coverage for CBD products under certain Medicare programs, even as the same products face an existential threat from recently passed federal legislation.
- CBD Market
Trump Ends Intoxicating Hemp Era, But Unintended Victims and Repeal Efforts Signal Turbulent Year Ahead
The sweeping redefinition of ‘hemp’ in the US following the passage of the funding bill threatens non-intoxicating CBD processors while pushing consumers toward unregulated markets President Donald Trump signed legislation on November 12 that brought the longest government shutdown in history to an end.
